Navigation Links
Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Date:4/5/2011

effective as vancomycin in clinical cure, and was superior to vancomycin in global cure, defined as cure without a recurrence after 4 weeks of therapy. The advisory committee referred to the global cure outcome as 30-day resolution, which we believe is indicative of DIFICID's benefit in reducing recurrences," said Sherwood Gorbach, M.D., Optimer's Chief Medical Officer. "While the advisory committee vote was split on how best to describe the recurrence benefit, the committee members overwhelmingly recognized that DIFICID at 30 days was superior to vancomycin. We appreciated the committee's discussion and look forward to working with the FDA as it considers our DIFICID NDA."

The AIDAC based its decision in part on the review of clinical evidence from the two largest, comparative Phase 3 clinical trials ever conducted against vancomycin in CDI. These multi-center, randomized, double-blind trials enrolled a total of 1,164 adults with confirmed CDI, who received either DIFICID (200 mg q12h) or vancomycin (125 mg q6h), the only FDA-approved product for the treatment of CDI. The objective of both studies was to show that a 10-day course of DIFICID was at least as efficacious (non-inferior) and safe as a 10-day course of vancomycin for the treatment of CDI. In both studies, DIFICID demonstrated a statistically significant reduction in the rate of recurrence compared with patients treated with vancomycin, reducing CDI recurrences by 47 percent, and was statistically superior to vancomycin in global cure rate (clinical cure without disease recurrence within four weeks). In addition, DIFICID met the primary endpoint of non-inferiority of clinical cure (defined as patients requiring no further CDI therapy two days after completion of study medication) compared to vancomycin.

DIFICID was safe and well tolerated in both studies, showing a similar incidence of treatment-related adverse events when compared to vancomycin.

Scheduled Conference Call


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Cohen, Placitella & Roth, PC is investigating potential ... Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 2011 through November 2, 2014 ("Class Period").  The ... officers and directors publically disseminated materially false and/or ... 20(a) of the Securities Exchange Act of 1934 ...
(Date:11/26/2014)... Md. , Nov. 26, 2014  Over 100 ... of those suffer from this pain daily. Chronic and ... of pain management is born to fulfill the need ... all types of pain. On October 28th, ... the Cumberland, Maryland community.  This ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3New Pain Management Center Opens in Cumberland, Md. 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced ... a Phase 2 clinical trial using intravenous administration ... in patients with non-small cell lung cancer (NSCLC) ... is Dr. Miguel Villalona-Calero, Professor, Division of Hematology/Oncology ...
... quantitative imaging endpoints from MRI analysesROCHESTER, N.Y., March ... ), a leading provider of quantitative imaging for ... Canadian medical device company based in Laval, Quebec, ... pivotal clinical trial for its cartilage repair device ...
Cached Medicine Technology:Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial 2VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial 3
(Date:11/28/2014)... a leader in the wig industry, has announced a great ... promotion features: , > 400 pieces of FOUR ... (no coupon code needed), > 10% off for ... $49 , Visit http://www.uniwigs.com for more details , The ... 1st and the first 100 shoppers each day will receive our ...
(Date:11/28/2014)... Georgia (PRWEB) November 28, 2014 Patten ... and locally grown. With those passions driving them, they've ... Georgia Grown. Having tried other pecans oils, they've found ... Pitts, Georgia to be exceptionally flavorful, retaining the buttery ... The same nutritional benefits found in pecans ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 An inventor from ... day to day. "I got this idea while lying in ... the bathroom," he said. , The Bed Buddy provides a ... go to the bathroom. It eliminates the need to leave ... promotes comfort and dignity. Easy to use and producible in ...
(Date:11/28/2014)... Before that Thanksgiving meal even had time to ... shopping season. Today, people will stand in line for hours ... retail shopping day of the year. , But instead ... Albany dentist Dr. Ronald Receveur is asking the public ... literally brighten a few smiles. , The gifts he suggests ...
(Date:11/28/2014)... Colorado (PRWEB) November 28, 2014 talklocal ... connect consumers to the right service professionals by phone in ... week after at least two tornadoes were reported to have ... Although no damage was reported following the tornadoes, Denver residents ... for the unexpected. Having TalkLocal is like having local pros ...
Breaking Medicine News(10 mins):Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 2Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 3Health News:New Albany Dentist Offers Gift Ideas That Can Improve Oral Health 4Health News:TalkLocal Launches In Denver A Week After Multiple Tornadoes Hit Near City 2
... Yet another Major Rise in Listeners. Affordable Health Insurance and ... ... Kansas City, MO (PRWEB) August 28, 2008 -- The Health Insurance ... September 6th on 1260 AM and 104.1 FM KSGF. The ...
... RDYN ) today announced the restructuring of ... 80% to 5 employees in,actions that are scheduled ... As a result of these actions Replidyne will ... for the,treatment of Clostridium difficile (C. difficile) bacteria ...
... Oncology has selected renowned pediatric oncologist Audrey Evans, M.D., ... recognized during the Awards Ceremony held Tuesday, September 23, ... Boston., Dr. Evans has been on the forefront of ... She was one of the co-founders of the original ...
... longer to see positive effect, researchers say , , WEDNESDAY, Aug. ... not lower the rate of stroke, cardiovascular events or diabetes ... stroke, a new study finds. , Telmisartan is an angiotensin ... chemicals that constrict the blood vessels enabling the blood to ...
... wages and benefits, HEMET, Calif., Aug. 27 The ... against the,board of directors of Valley Health System (VHS) for ... already voted to agree to., "I do this job ... said,Lisa Howell, a registered nurse at Menifee Valley Medical Center. ...
... use 7 simple variables to gauge in-hospital mortality ... News) -- A new scoring system for assessing ... been confirmed to be effective, according to Mayo ... The Mayo Clinic Risk Score (MCRS) uses seven ...
Cached Medicine News:Health News:The Health Insurance Advocate Radio Show Expands to Springfield, Missouri, and Reaches a New All-Time Ratings High for Female Listenership 2Health News:The Health Insurance Advocate Radio Show Expands to Springfield, Missouri, and Reaches a New All-Time Ratings High for Female Listenership 3Health News:Replidyne Announces Restructuring of Operations 2Health News:ASTRO selects pediatric oncologist as 2008 honorary member 2Health News:Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke 2Health News:Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke 3Health News:State Board Issues Complaint: VHS Board Should Have Signed Contract With Caregivers 2Health News:Angioplasty Scoring System Predicts Risk of Death 2
20 g MVR knife. Dimensions: 31.8 mm x 1.18 mm x 2.7 mm....
Full Handle Laseredge Spoon Blade Knife, 3.0 mm angled double bevel. Blade dimension: 11.0 mm (L) x 3.0 mm (W). Cut: 320....
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.2 mm x 4.0 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Medicine Products: